ProCE Banner Activity

BELIEVE: HRQoL Outcomes for Patients With Transfusion-Dependent β-Thalassemia Treated With Luspatercept

Slideset Download
Conference Coverage
HRQoL was sustained in the phase III BELIEVE study of luspatercept vs placebo in transfusion-dependent β-thalassemia.

Released: December 14, 2020

Expiration: December 13, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology